Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031
Awa Sarr(University of St Andrews), Paul A. Reynolds(University of St Andrews)
Cited by 17
Related Papers
Abstract 1855: NUC-1031 overcomes resistance associated with gemcitabine in cancer patients
|Cancer Research|2018|2